The effects of DL-3-n-butylphthalide in patients with acute large area cerebral infarction: a observational study .

To evaluate the medication administration effects of DL-3-n-butylphthalide in patients with acute large area cerebral infarction in three months: a multicentre, prospective, observational study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046518

Enrollment

Unknown

Registered

2021-05-19

Start date

2016-01-01

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute large area cerebral infarction

Interventions

not receive NBP group:Nil

receive NBP group:Nil

Eligibility

Sex/Gender

All

Age

22 Years to 97 Years

Inclusion criteria

Inclusion criteria: 1. Initial cerebral infarction; 2. Large area cerebral infarction tested with MR and CT brain images; 3. Infarction diameter > 4cm, and infarction occurring to at least two lobes; 4. Attack time <= 72h; 5. Patients received or not received 200?mg NBP injection for 7-14 days and 200?mg of NBP capsules three times daily for 30-90 days respectively.

Exclusion criteria

Exclusion criteria: 1. Patients with intracerebral hemorrhagic diseases and hemorrhagic tendency of other system; 2. Severe conscious disturbance with GCS <= 7; 3. Patients with severe primary heart and lung diseases, liver and renal insufficiency; 4. Patients with severe mental diseases or dementia; 5. Patients with other brain organic diseases like brain tumors.

Design outcomes

Primary

Measure	Time frame
Modified Rankin Scale;	—

Secondary

Measure	Time frame
National Institute of Health stroke scale;Barthel Index;	—

Countries

China

Contacts

Public ContactZhang Xu

The First Affiliated Hospital of Wenzhou Medical University

drzhangxu@live.cn+86 577 55579372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026